Effects for glucose metabolism, body composition, and circulatory dynamics of SGLT2 inhibitor

Effects for glucose metabolism, body composition, and circulatory dynamics of SGLT2 inhibitor - Pleiotropic effects of SGLT2 inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017195

Enrollment

Registered

2015-04-22

Start date

2015-04-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

SGLT2 inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with type 2 diabetes. HbA1c: 6.5%~9.0%

Exclusion criteria

Exclusion criteria: 1. The patients with severe macroangiopathy 2. The patients with severe renal and/or liver dysfunction. 3. Women who were pregnant, lactating, or capable of pregnancy

Design outcomes

Primary

Measure	Time frame
The changes of glucose metabolism, incretin secretion, gut peptides secretion, body weight, body composition, and basal metabolic rate.	—

Countries

Japan

Contacts

Public ContactHiroaki Ueno

Faculty of Medicine, University of Miyazaki Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine

intron@med.miyazaki-u.ac.jp0985-85-2965

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026